{"id":15109,"date":"2026-06-26T18:11:02","date_gmt":"2026-06-26T12:41:02","guid":{"rendered":"https:\/\/mdforlives.com\/blog\/?p=15109"},"modified":"2026-06-26T18:11:02","modified_gmt":"2026-06-26T12:41:02","slug":"adcs-in-oncology","status":"publish","type":"post","link":"https:\/\/mdforlives.com\/blog\/adcs-in-oncology\/","title":{"rendered":"ADCs in Oncology: When Clinical Promise Moves Faster Than Practice Confidence"},"content":{"rendered":"

A therapy can look highly promising in a trial and still feel conditional at the bedside.<\/span>\u00a0<\/span><\/p>\n

That is where antibody-drug conjugates now sit in oncology practice. ADCs have moved from specialist enthusiasm into real treatment conversations across solid tumors. Their design is compelling: an antibody directs a cytotoxic payload toward tumor cells expressing a specific target, aiming to combine precision with potency. In principle, that should make ADCs feel like a cleaner evolution of systemic therapy.<\/span>\u00a0<\/span><\/p>\n

In practice, oncologists are describing something more nuanced.<\/span>\u00a0<\/span><\/p>\n

Like car T cell therapy<\/a>, ADCs represent a major step toward precision oncology, but their real-world success depends not only on clinical efficacy, but also on patient selection, toxicity management, and thoughtful treatment sequencing.<\/p><\/blockquote>\n

The current question is no longer whether ADCs matter. They clearly do. The harder question is how confidently they can be selected, sequenced, and managed when patients no longer resemble trial populations.<\/span>\u00a0<\/span><\/p>\n

An MDForLives pulse survey among oncologists across major markets in North America and Western Europe shows this clearly. ADCs are advancing, but practice confidence is not advancing at the same speed.<\/span><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n